GO45322 A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES

  • Phase II
  • Trial Category: Breast

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*